National Cancer Institute Selects ImmunityBio's N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free TherapyBusiness Wire • 10/04/21
ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 TrialBusiness Wire • 09/13/21
ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement ExecutivesBusiness Wire • 09/07/21
ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association's Annual MeetingBusiness Wire • 09/01/21
ImmunityBio Appoints Dr. Patrick Soon-Shiong to Global Chief Scientific and Medical Officer; Newly Created Role Will Lead Company's Scientific Strategy and Global ExpansionBusiness Wire • 08/16/21
CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022Business Wire • 07/29/21
ImmunityBio's Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. PatentBusiness Wire • 07/27/21
ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19Business Wire • 07/14/21
ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer PatientsBusiness Wire • 06/28/21
FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast CancerBusiness Wire • 06/15/21
ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study' in Patients Off Therapy and a Phase 2 Study in Acutely Infected PatientsBusiness Wire • 06/10/21
ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a ‘Universal Boost' in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South AfricaBusiness Wire • 05/25/21
ImmunityBio to Present Preliminary Phase 2 Data of 68% Durable Disease Control with Anktiva Plus Checkpoint Inhibitor in First 140 Patients Enrolled with Lung Cancer and Multiple Tumor Types Who Failed Prior Checkpoint Therapy at ASCO 2021Business Wire • 05/20/21
ImmunityBio Shares Jump As It Plans To Start Testing Memory Cytokine-Enriched NK Cell Platform In Solid Tumors PatientsBenzinga • 05/17/21
FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid TumorsBusiness Wire • 05/17/21
ImmunityBio Announces 78 Percent Complete Response Following Chemotherapy-Free Combination of IL-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma PatientsBusiness Wire • 05/04/21
ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV ReservoirsBusiness Wire • 04/29/21
ImmunityBio Announces 100th Patient Dosed with Proprietary Natural Killer Cells; NK Trials Cover Multiple IndicationsBusiness Wire • 04/22/21
ImmunityBio: Remaining Bullish As Global Vaccine Apparatus Continues To MisfireSeeking Alpha • 04/16/21
